Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

• J.L. Boormans,
• R. De Wit,
• G.S. Kulkarni,
• E.M. Uchio,
• M. Roumiguié,
• L.E.M. Krieger,
• E.A. Singer,
• D.F. Bajorin,
• A.M. Kamat,
• P. Grivas,
• H.K. Seo,
• H. Nishiyama,
• B.R. Konethy,
• T. Saretsky,
• H. Li,
• K. Nam,
• E. Kapadia,
• A.V. Balar

Affiliations

J.L. Boormans

R. De Wit

G.S. Kulkarni

E.M. Uchio

M. Roumiguié

L.E.M. Krieger

E.A. Singer

D.F. Bajorin

A.M. Kamat

P. Grivas

H.K. Seo

H. Nishiyama

B.R. Konethy

T. Saretsky

H. Li

K. Nam

E. Kapadia

A.V. Balar